The G0/G1 Switch Gene 2 Is an Important Regulator of Hepatic Triglyceride Metabolism

Yinfang Wang,1,2* Yahui Zhang,2* Hang Qian,1 Juan Lu1,2, Zhifeng Zhang,1,2, Xinwen Min,1 Mingjian Lang,1 Handong Yang,1 Nanping Wang,4 Peng Zhang1,2*

1 Cardiovascular Research Center, Hubei University of Medicine, Hubei, China, 2 Department of Physiology, Hubei University of Medicine, Hubei, China, 3 Department of Pathophysiology, Hubei University of Medicine, Hubei, China, 4 Cardiovascular Research Center, Xi'an Jiaotong University School of Medicine, Xi'an, China

Abstract

Nonalcoholic fatty liver disease is associated with obesity and insulin resistance. Factors that regulate the disposal of hepatic triglycerides contribute to the development of hepatic steatosis. G0/G1 switch gene 2 (G0S2) is a target of peroxisome proliferator-activated receptors and plays an important role in regulating lipolysis in adipocytes. Therefore, we investigated whether G0S2 plays a role in hepatic lipid metabolism. Adenovirus-mediated expression of G0S2 (Ad-G0S2) potently induced fatty liver in mice. The liver mass of Ad-G0S2-infected mice was markedly increased with excess triglyceride content compared to the control mice. G0S2 did not change cellular cholesterol levels in hepatocytes. G0S2 was found to be co-localized with adipose triglyceride lipase at the surface of lipid droplets. Hepatic G0S2 overexpression resulted in an increase in plasma Low-density lipoprotein (LDL)/Very-Low-density (VLDL) lipoprotein cholesterol level. Plasma High-density lipoprotein (HDL) cholesterol and ketone body levels were slightly decreased in Ad-G0S2 injected mice. G0S2 also increased the accumulation of neutral lipids in cultured HepG2 and L02 cells. However, G0S2 overexpression in the liver significantly improved glucose tolerance in mice. Livers expressing G0S2 exhibited increased 6-(N-(7-nitrobenz-2-oxa-1-3-diazol-4-yl) amino)-6-deoxyglucose uptake compared with livers transfected with control adenovirus. Taken together, our results provide evidence supporting an important role for G0S2 as a regulator of triglyceride content in the liver and suggest that G0S2 may be a molecular target for the treatment of insulin resistance and other obesity-related metabolic disorders.

Introduction

Hepatic steatosis, also called fatty liver, is caused by the abnormal retention of triglycerides and other fats within liver cells. Obesity, diabetes, and excessive alcohol consumption may contribute to hepatic steatosis [1–3]; more than 50% of all cases with type 2 diabetes have hepatic steatosis. High hepatic triglyceride concentrations are significantly associated with increased fasting insulin levels. It is recognized that hepatic steatosis is a predictor of insulin resistance [1,2]; moreover, hepatic steatosis is also independently associated with the presence and extent of coronary artery disease and other illnesses [4–6].

Within the liver, triglycerides accumulate in lipid droplets, and their deposition is dependent on their biosynthesis and elimination rates [7]. A decreased rate of triglyceride turnover facilitates triglyceride accumulation in the liver [8,9]. A large number of molecules can regulate the generation or disposal of hepatic triglycerides.

G0/G1 switch gene 2 (G0S2) was initially found to be differentially expressed in lymphocytes during the lectin-induced switch from the G0 to G1 phase of the cell cycle [10,11]. Both human and mouse G0S2 genes encode a protein of 103 amino acids with 78% sequence homology. Later, it was reported that G0S2 mRNA is also highly expressed in brown and white adipose tissue and up-regulated during growth arrest in 3T3-L1 fibroblasts [12]. The activation of peroxisome proliferator-activated receptors (PPAR)-γ and -α [12], PPAR-β/δ [13], and retinoic acid [14,15] as well as insulin stimulation can upregulate G0S2 expression in 3T3-L1 cells and human
acute promyelocytic leukemia cells. Recently, Yang et al. reported that G0S2 inhibits the triglyceride hydrolase activity of adipose triglyceride lipase (ATGL), a major regulator of lipid metabolism in mammals [8], suggesting that G0S2 may play an important role in regulating lipolysis in adipocytes [16]. ATGL is also a major lipase in the liver. However, the expression and function of G0S2 in the liver are still unknown at the present time; therefore, in this study, we examined the biological role of G0S2 in lipid homeostasis in the liver.

Materials and Methods

Cell culture and reagents
HepG2, a hepatocytoma cell line, and L02, a normal hepatic cell line (China Center for Type Culture Collection, Wuhan, China), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM L-glutamine in 5% CO2 at 37° C. DMEM and FBS were purchased from Invitrogen (Carlsbad, CA, USA). Antibodies against G0S2 (N-13), ATGL (F-7), and horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). FITC-conjugated donkey anti-rabbit and TRITC-conjugated goat anti-mouse antibodies were from Proteintech Group, Inc. (Chicago, IL, USA).

Adenovirus construction and infection
An adenovirus (Ad) expressing G0S2 was constructed using Adeno-X Expression System 2 following the manufacturer’s instruction (Clontech, CA, USA). Briefly, the full-length coding region of G0S2 was subcloned into the pDNA-CMV vector and transferred to the pLP-Adeno-X-CMV Acceptor Vector via Cre-loxP-mediated recombination. The Ad was amplified and purified using the cesium chloride method. Cells were infected with the Ad at a multiplicity of infection (MOI) of 100.

Plasmid construction and transfection
We used the pAc-GFP-C1 vector to construct plasmids for the eukaryotic expression of the full-length coding region of the human G0S2 gene. All plasmids were constructed using In-Fusion™ Dry-Down PCR Cloning Kit according to the manufacturer’s protocol (Clontech, CA, USA). Plasmids were purified using the Promega PureYield Plasmid System. Cultured cells were transfected with the Ac-GFP-G0S2 plasmid.
using the Lipofectamine™ LTX Reagent (Invitrogen, Carlsbad, CA, USA) and incubated for 24 h. Immunofluorescence was visualized using a laser scanning confocal microscope (Zeiss, Leusden, the Netherlands).

**Animal experiments**

All experiments using mice were conducted according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publications No. 85-23, revised 1996) and approved by the Animal Care and...
Use Committee of Hubei University of Medicine. Male 4-week-old Swiss mice were used in all experiments. The animals were fed with standard rodent chow and maintained on a 12-h artificial light-dark cycle. Ad-LacZ or Ad-G0S2 (3.0 × 10^9 pfu) in 100 µL sterilized phosphate-buffered saline (PBS) was delivered by tail vein injection. Diabetes was induced by multiple subdiabetogenic intraperitoneal (i.p.) injections of streptozotocin (STZ) freshly dissolved in 10 mM Na-citrate buffer (pH 4.5) (50 mg STZ/kg body weight daily for 5 consecutive days) (Sigma, MO, USA). The experimental group of mice had food withdrawn for 16 h, with ad libitum access to water, previous to sacrifice. Liver tissue was removed for the measurements of organ weight and triglyceride content, RNA and protein extraction, and histological examinations.

Glucose tolerance test and insulin tolerance test (ITT)

For the oral glucose tolerance test, the mice were fasted overnight, and then, a 2 g/kg body weight glucose solution was administered orally. Blood samples were collected from the tail before and at 30, 60, and 90 min after the glucose challenge for determination of blood glucose levels. For the ITT, the mice were fasted overnight. After measuring body weight and glucose levels, insulin (Sigma) was injected into each mouse i.p. (0.2 U/kg body weight). Blood glucose levels were measured using a glucose meter at 15, 30, 60, and 90 min after the insulin challenge.

Oil Red O staining

Freshly dissected liver was fixed overnight in 4% paraformaldehyde, cryoprotected in 30% sucrose in PBS for another day, and then frozen in OCT blocks. Cryostat sections 7 µm thick were processed for Oil Red O staining; thereafter, the slices were fractionated with 60% isopropanol for 1 min and washed with PBS for 2 min. To measure the cellular accumulation of neutral lipid droplets, HepG2 and L02 cells were fixed in 4% paraformaldehyde and stained with Oil Red O solution for 30 min at room temperature. The cells were washed with 60% isopropanol. After staining, the cells were washed with PBS to remove unbound dye. To quantify Oil Red O content, the samples were treated with isopropanol and read using a spectrophotometer at 510 nm.

Hepatic and serum parameters

Triglyceride and cholesterol levels in the liver and cells were measured using colorimetric kits from Abcam (Cambridge, MA, USA) according to the manufacturer’s instructions. Blood for the determination of lipid parameters was obtained from fasted mice. High-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)/very-low-density (VLDL) lipoprotein...
cholesterol, and ketone bodies in serum samples were evaluated, respectively, using colorimetric kits from BioAssay Systems (Hayward, CA, USA) and a β-Hydroxybutyrate Colorimetric Assay Kit from Abcam (Cambridge, MA, USA) according to the manufacturer’s instruction. A Free Fatty Acid Quantification Kit was purchased from BioVision (Milpitas, CA, USA).

Figure 5. Overexpression of G0S2 improves glucose tolerance in mice. (A) G0S2 mRNA levels in liver following ad libitum feeding, a 12 h fast, or ad libitum refeeding for 12 h following the 12 h fast. (B) The expression of G0S2 mRNA in the liver of control mice and mice treated with STZ. Blood glucose levels and the inverse integrated area under the glucose curve of mice at 4 (C, D) or 8 (E, F) days after injection with Ad-LacZ or Ad-G0S2. Change in plasma glucose levels (G) and the mean area under the curve (H) after an ITT in mice. *P < 0.05, compared with the Ad-LacZ-infected mice (n = 6).

doi: 10.1371/journal.pone.0072315.g005
Co-immunoprecipitation and western blot analyses

For the co-immunoprecipitation assays, 300 µg of total protein extract from mouse livers were immunoprecipitated with the anti-ATGL antibody or pre-immune IgG by using a Dynabeads® Co-Immunoprecipitation Kit (Invitrogen, CA, USA) and then subjected to western blot analysis with the anti-G0S2 antibody. Equal amounts of total protein (30 µg) were also resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes for western blot analysis. The membranes were probed with a primary antibody followed by a secondary antibody conjugated with horseradish peroxidase. The immunocomplexes were visualized with Enhanced Chemiluminescence Plus (Amersham Pharmacia Biotech, NJ, USA).

Measurement of glucose uptake

Glucose uptake by hepatic cells was assessed in vivo. A fluorescent d-glucose analog, 6-(N-(7-nitrobenz-2-oxa-1,3-dioxol-4-yl) amino)-6-deoxyglucose (6-NBDG; Invitrogen, CA, USA), was used to detect glucose uptake by the liver. LacZ- or G0S2-infected mice were fasted overnight and then a glucose solution (2 g/kg) was administered orally. Fifty minutes later, 100 µL of 2 mM 6-NBDG was injected intravenously via the tail vein into each mouse. Another 15 min later, the animals were perfused with PBS via the left ventricle. The liver was minced and homogenized in a lysis buffer supplemented with a protease inhibitor cocktail. The soluble fraction was obtained by centrifugation. The 6-NBDG content in equal amounts of protein lysate was measured by fluorescence intensity (excitation/emission of ~465/540 nm).

Statistical analysis

Data are expressed as the mean ± standard error of the mean (SEM). Differences were assessed by analysis of the variance or Student’s t-test. P-values less than 0.05 were considered statistically significant.

Results

Overexpression of G0S2 induced hepatic steatosis

To determine the in vivo hepatic function of G0S2, a recombinant Ad expressing G0S2 was generated. The mice were injected via the tail vein with the Ad vectors. The expression of G0S2 protein in the liver and fat tissues were verified by western blot analysis (Figure 1A). After 4 or 8 days of infection, the livers were harvested and weighed. The Ad-G0S2-infected mice exhibited typically larger livers than the Ad-LacZ-infected animals (Figure 1B). Liver weight in the Ad-G0S2-infected mice was approximately 1.4-fold greater than that of the Ad-LacZ control mice (Figure 1C). The livers were subsequently sectioned and stained with Oil Red O, which stains neutral lipids. The number and size of lipid droplets were significantly increased in the Ad-G0S2-infected livers compared to the Ad-LacZ-infected livers (Figure 1D).

We further analyzed the effect of G0S2 overexpression on lipid content. The triglyceride content of Ad-G0S2-infected livers was significantly increased compared to the Ad-LacZ-infected livers (30.30 ± 4.72 µmol/g tissue vs. 10.71 ± 2.14 µmol/g tissue at day 4; 27.57 ± 5.05 µmol/g tissue vs. 9.00 ± 1.40 µmol/g tissue at day 8, respectively) (Figure 1E). The Ad-G0S2-infected animals also exhibited elevated plasma triglyceride levels (Figure 1F). Glycerol levels in the Ad-G0S2-infected livers were lower than in the control livers (Figure 1G); however, the Ad-G0S2-infected animals exhibited elevated hepatic free fatty acid levels (Figure 1H). The levels of free cholesterol and esterified cholesterol in the liver remained unchanged (data not shown). These results suggest that G0S2 overexpression induced the accumulation of triglycerides and promoted fatty liver formation.

Effect of G0S2 on the levels of plasma HDL cholesterol, LDL/VLDL cholesterol, and ketone bodies

Systemic free fatty acids are the major substrate for VLDL-TAG and ketone body 3-hydroxybutyrate production. HDL cholesterol and LDL cholesterol are two major components of cholesterol. We first examined the effect of G0S2 overexpression on HDL cholesterol and LDL/VLDL cholesterol levels in plasma. The resulting data showed that G0S2 overexpression increased LDL/VLDL cholesterol levels, while it slightly decreased HDL cholesterol levels in plasma (Figure 2A, 2B). However, the levels of plasma free fatty acids and glycerol remained unchanged (Figure 2C, 2D). Reportedly, ATGL regulates fatty acid oxidation. We further investigated the effect of G0S2 overexpression on ketone body production. Reduced ketone body production was observed in the mice injected with Ad-G0S2 compared to the control mice (Figure 2E).
G0S2 was coupled with ATGL in the mouse liver

Since G0S2 functionally associates with ATGL and regulates its action in adipocytes, we examined whether G0S2 physically interacts with ATGL in the mouse liver. The subcellular localization of G0S2 and ATGL was determined by using immunofluorescence staining. LDs in the liver were visualized under a phase-contrast microscope and confirmed using Oil Red O staining. G0S2 was found to be localized at the surface of lipid droplets and co-localized with ATGL (Figure 3A). To confirm this observation, we evaluated the interaction between G0S2 and ATGL using a co-immunoprecipitation assay. Immunoblotting of the ATGL-immunoprecipitates from the liver lysates showed that G0S2 co-precipitated with ATGL (Figure 3B), confirming that G0S2 interacts with ATGL in the liver.

Changes in the expression levels of mRNAs encoded by PPAR target genes

Lipolysis of cellular triglycerides by ATGL generates mediators involved in the generation of lipid ligands for PPAR activation. ATGL deficiency in mice can decrease the mRNA levels of PPAR-α and PPAR-δ target genes in cardiomyocytes. We examined the expression of p2, Cyp4a10, Ehhadh, Fgf21, and Aldh3a2 mRNA in the liver. The resulting data showed that the mRNA levels of Ehhadh and Aldh3a2 in the liver were reduced in the Ad-G0S2-infected mice compared to the control mice. G0S2 overexpression did not alter aP2 or Cyp4a10 expression (Figure 4A–D). We further investigated the effect of G0S2 overexpression on the mRNA levels of genes involved in lipolysis, e.g., Lipe and Cgi58. The data showed that hepatic G0S2 overexpression in mice decreased the mRNA levels of Lipe, but did not alter Cgi58 or Atgl expression (Figure 4E–G).

G0S2 overexpression improves glucose tolerance

Hepatic steatosis is associated with insulin resistance. To study the regulation of G0S2 expression by insulin, we performed a fasting/refeeding experiment. G0S2 mRNA levels fell slightly upon fasting and were restored by refeeding (Figure 5A). Furthermore, STZ injection caused G0S2 levels to decrease by 30% in the liver (Figure 5B). We next investigated the ability of G0S2 overexpression to influence glucose tolerance in vivo. We found that overexpression of G0S2 in the liver significantly improved glucose tolerance (P < 0.05 at 30 and 60 min) at days 4 (Figure 5C, 5D) and 8 (Figure 5E, 5F) post-infection. Fasting glucose levels were not significantly different between the Ad-G0S2- and Ad-LacZ-infected groups. These results demonstrate that G0S2 modulates glucose as well as lipid homeostasis in vivo. We further carried out an ITT in mice fed a chow diet. Overexpression of G0S2 in the liver resulted in a slightly, but not significantly, hypoglycemic response to insulin compared with the control mice (Figure 5G, 5H). Therefore, hepatic G0S2 overexpression improves glucose disposal in vivo.

G0S2 overexpression increases hepatic glucose uptake

To further assess whether G0S2 affect glucose uptake by the liver, we examined the fluorescence intensity of 6-NBDG in

Figure 7. G0S2 causes lipid accumulation in hepatocyte cell lines. (A) L02 cells were transfected with the Ad-GFP-G0S2 plasmid and incubated under normal growth conditions for 24 h. The cells were fixed and stained with Oil Red O and then observed under fluorescence microscopy. (B) G0S2 protein levels in the L02 cells were determined with western blotting. (C) HepG2 or L02 cells were infected with Ad-LacZ or Ad-G0S2 for 48 h before they were fixed and stained with Oil Red O. Representative images are shown (magnification 400×). (D) Oil Red O content in HepG2 and L02 cells. (E and F) Triglyceride and cholesterol levels in L02 cells. Each bar represents the mean ± SEM (n = 3). *P < 0.05; ns, not significant.

doi: 10.1371/journal.pone.0072315.g007
equal amounts of hepatic protein lysate. It was shown that the fluorescence intensity of 6-NBDG was significantly increased in the Ad-G0S2-infected livers compared to the Ad-LacZ-infected livers (Figure 6). These data indicate that G0S2 enhances glucose tolerance by increasing hepatic glucose uptake.

**G0S2 resulted in lipid accumulation in hepatocytes in vitro**

Whether G0S2 directly modulates the lipid content of hepatocytes was further examined in vitro. The GFP-G0S2 fusion protein was expressed in L02 cells; lipid droplets were stained with Oil Red O. Here, we found that GFP-G0S2 protein was located in the proximity of the lipid droplets of L02 cells (Figure 7A). The overexpression of G0S2 protein in the Ad-infected L02 cells was verified by western blot analysis (Figure 7B). In accordance with the in vivo results, G0S2 overexpression significantly increased neutral lipid content in L02 and HepG2 cells compared with control cells (Figure 7C, 7D). Cholesterol and triglyceride content in the L02 cells was analyzed subsequently. The resulting data showed that G0S2 overexpression caused an approximately 1.5-fold increase in cellular triglyceride content, but did not change cellular cholesterol levels in hepatocytes (Figure 7E, 7F).

**Discussion**

In the present study, we found that the overexpression of G0S2 induces triglyceride accumulation in the mouse liver and results in the development of hepatic steatosis. G0S2 overexpression can increase LDL/VLDL cholesterol levels and decrease HDL cholesterol and ketone body levels in the blood. G0S2 couples with ATGL and promotes lipid accumulation in hepatocytes. However, G0S2 overexpression in the liver has beneficial effects on glucose homeostasis. These findings suggest that G0S2 is a crucial regulator of hepatic triglyceride metabolism.

Although G0S2 was first identified as a potential cell cycle regulator, it has been shown that G0S2 expression is restricted to forming brown adipose tissue and liver during murine embryonic development [17]. Similarly, Zandbergen et al. showed that G0S2 is a PPAR target gene; G0S2 mRNA levels were the highest in brown and white adipose tissue and were greatly up-regulated during the adipogenesis of mouse 3T3-L1 cells [12]. These data give a clue that G0S2 may participate in lipid metabolism. Yang et al. recently reported that G0S2 localizes to lipid droplets and prevents their ATGL-mediated turnover in HeLa cells and adipocytes [16]. The liver and adipose tissue are the main sites of triglyceride synthesis. In the present study, we provided direct evidence that G0S2 induced liver triglyceride accumulation and severe hepatic steatosis under basal conditions.

It is known that PPAR agonists decrease hepatic lipid content in humans and rodents [18,19]. A therapeutic dose of a PPAR-α agonist increased the liver triglyceride levels in mice [20]. Fenofibrate treatment of rats resulted in a 50% increase in liver triglyceride levels [21]. Moreover, bezafibrate, an agonist of murine PPAR-α and a partial agonist of PPAR-γ, increased cellular triglyceride mass in primary rat hepatocytes [22]. On the contrary, a PPAR-α agonist increased hepatic triglyceride content less in animals that received a high-fat diet [23–26]. In this study, we also found that the mRNA expression of G0S2 in the liver was up-regulated (approximately 2-fold induction) by fenofibrate (data not show). Therefore, G0S2 is likely to play a role in the maintenance of the liver triglyceride pool under physiological conditions. It is possible that the modulation of liver triglyceride levels by PPAR-α agonists is at least partially achieved via the induction of G0S2. Moreover, it is likely that G0S2 is also a negative regulator of PPAR agonists and may counterbalance the triglyceride lowering effects of PPAR under pathophysiological conditions.

Fatty acids are broken down enzymatically by β-oxidation to form acetyl-CoA. The ATGL-mediated hydrolysis of triglycerides generates fatty acids and diacylglycerol (DAG). Reportedly, fatty acid oxidation was increased by ATGL overexpression and decreased by ATGL knockdown [27]. The current study provided evidence that the overexpression of G0S2 in the liver partly decreased the levels of serum ketone bodies. Given that G0S2 interacts directly with ATGL to suppress its enzymatic activity, it is speculated that G0S2 mediated the down-regulation of ketone body production by suppressing free fatty acid levels or hepatic fatty acid oxidation. Reportedly, the lipolysis of cellular triglycerides by ATGL generates mediators that are involved in the generation of lipid ligands for PPAR activation. ATGL could also influence PPAR-α activity independently of ligand-induced activation [28]. We found that the administration of Ad-G0S2 decreased Ehhadh and Aldh3a2 mRNA levels, but did not significantly change Acox1 or Cyp4a10 mRNA expression in the liver. Therefore, it is suggested that G0S2 influenced ketone body formation partly independently of PPAR ligand-induced activation.

Endogenous ATGL is localized to the external surface of lipid droplets in adipocytes, and it plays a key role in lipid droplet/ adiposome degradation in mammalian cells. G0S2 couples with ATGL and prevents ATGL-mediated basal lipid droplet degradation in adipocytes and HeLa cells [16]. Recent work by Lu et al. demonstrated that G0S2 binds to ATGL in a manner that is dependent on the intact 3-dimensional structure of the patatin-like domain and may block the substrate accessibility of ATGL [29]. In this study, we demonstrated that G0S2 and ATGL were colocalized on the surface of lipid droplets. Immunoprecipitation confirmed that G0S2 binds directly with ATGL in hepatocytes. A previous study showed that hepatic overexpression of ATGL stimulates the direct release of free fatty acids. Here, we found that Ad-G0S2-infected animals exhibit elevated hepatic free fatty acid levels. We hypothesize that increased hepatic triglyceride storage pools and decreased direct release of free fatty acids could result in elevated hepatic free fatty acid levels. Furthermore, glycerol levels in Ad-G0S2-infected livers were decreased compared with controls. Collectively, these observations indicate that G0S2 can decrease triglyceride degradation in hepatocytes through binding with ATGL and inhibiting its activity.

It is worth noting that G0S2-induced hepatic steatosis was very potent (by 3-fold) in vivo, but to a lesser extent (1.5-fold) in hepatocytes in vitro. Lipid droplets of Ad-G0S2-infected livers in vivo were also significantly larger than those seen in Ad-
GOS2-infected HepG2 and L02 cells in vitro. To address this discrepancy, physiological concentrations of oleic acid were added to the culture media; however, GOS2-induced hepatic lipid accumulation in hepatocytes in vitro was still much weaker than in vivo (data not shown). Furthermore, a high MOI still could not increase lipid accumulation in hepatocytes. The differences between the in vitro and in vivo results may indicate that internal conditions can modulate GOS2 activity and the global metabolic effects of GOS2 may also contribute to the development of hepatic steatosis.

A number of studies have documented a strong relationship between hepatic steatosis and insulin resistance. Hepatic steatosis is thought to be part of metabolic syndrome [2,30]. GOS2 expression in fat tissue was found to be decreased in db/db mice and mice fed with a high-fat diet. We reported here that STZ treatment also decreased the expression of GOS2 mRNA in the liver. Insulin increased but TNF-α decreased the expression in hepatocytes was upregulated by high glucose. Here, we unexpectedly found that the overexpression of GOS2 in the liver increased glucose disposal in vivo. Discrepant effects on insulin sensitivity and hepatic steatosis have been observed in several recent studies. Reportedly, liver-specific Akt activation [32], angiopoietin-like protein 4 overexpression [33], and inhibition of phosphatase and tensin homolog [34] improved glucose tolerance, but induced hyperlipidemia and hepatic steatosis in mice. Moreover, GOS2 attenuates ATGL action. ATGL null mice store vast amounts of triacylglycerol in key glucoregulatory tissues, yet exhibit enhanced insulin sensitivity and glucose tolerance [35]. Previous evidence also showed that the reduced availability of ATGL-derived free fatty acids lead to increased glucose use [36]. Furthermore, ATGL cleaves the first fatty acid to create DAG. Reportedly, ATGL overexpression could promote DAG accumulation and disrupt insulin signaling and action in myotubes [37]. Hepatic DAG content was found to be strongly correlated with the activation of hepatic PKCε, which impairs insulin signaling [38]. Recently, Ong et al. reported that hepatic ATGL knockdown decreased glucose production and increased glucose oxidation in the liver [28]. Thus, GOS2 could probably improve glucose tolerance by inhibiting ATGL activity. However, it seems that hepatic glucose uptake is minimal compared to peripheral glucose uptake. Furthermore, we also have no idea whether GOS2 overexpression regulates hepatic insulin signaling activation. Therefore, these data indicate that hepatic glucose uptake at least partially contributed to the enhanced glucose tolerance of mice infected with Ad-GOS2. The detailed mechanisms for the improvement of glucose homeostasis by GOS2 still remain to be elucidated.

In summary, our present study provided experimental evidence supporting an important role for GOS2 as a regulator of triglyceride content in the liver. Further investigations are needed to address the functions of GOS2 in the pathophysiology of obesity-related hepatic steatosis in humans.

Author Contributions

Conceived and designed the experiments: PZ. Performed the experiments: YFW YHZ HQ JL ZFZ. Analyzed the data: XWM.

Role of GOS2 in Liver

References

1. Leavens KF, Bimbaum MJ (2011) Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 46: 200-215. doi:10.3109/10409238.2011.562481. PubMed: 21599535.
2. Richard J, Lingvay I (2011) Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 9: 321-328. doi:10.1586/erc.11.15. PubMed: 21438811.
3. Samuel VT, Liu ZX, Xu X, Elder BD, Bilz S et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279: 32345-32353. doi:10.1074/jbc.M313478200. PubMed: 15166226.
4. Santos RD, Nasir K, Conceição RD, Sarwar A, Carvalho JA et al. (2007) Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men. Atherosclerosis 194: 517-519. doi:10.1016/j.atherosclerosis.2007.01.026. PubMed: 17339826.
5. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13: 376-386. doi:10.1016/j.cmet.2011.03.009. PubMed: 21459323.
6. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G et al. (2004) Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27: 2498-2500. doi:10.2337/diacare.27.10.2498. PubMed: 15451925.
7. Marmugi A, Duchex S, Lasserre F, Pollici A, Paris A et al. (2012) Low doses of bisphenol A induce gene expression related to lipid synthesis and trigger triglyceride accumulation in adult mouse liver. Hepatology 55: 395-407. doi:10.1002/hep.24685. PubMed: 21932408.
8. Ong KT, Mashek MT, Bu SY, Greenberg AS, Mashek DG (2011) Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology 53: 116-126. doi:10.1002/hep.24006. PubMed: 20967758.
9. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG et al. (2006) Targeting f oxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55: 2042-2050. doi:10.2337/db05-0705. PubMed: 16804074.
10. Nakamura N, Shimaoka Y, Togau T, Onoda H, Okuzaki D et al. (2006) Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. DNA Res 13: 169-183. doi:10.1093/dnares/dsl008. PubMed: 17082220.
11. Russell L, Fosdyke DR (1991) A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol 10: 581-591. doi: 10.1089/dna.1991.10.581. PubMed: 1930693.
12. Zandbergen F, Mandard S, Escher P, Tan NS, Patsours D et al. (2005) The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J 392: 313-324. doi:10.1042/BJ20050636. PubMed: 16088669.
13. Teunissen BE, Smeets PJ, Willemsen PH, De Windt LJ, Van der Vusse GJ et al. (2007) Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc Res 75: 519-529. doi:10.1016/j.cardiores.2007.04.026. PubMed: 17543901.
14. Cheng YH, Utsunomiya H, Pavone ME, Yin P, Bulun SE (2011) Retinoic acid inhibits endometrial cancer cell growth via multiple genomic mechanisms. J Mol Endocrinol 46: 139-153. doi:10.1530/JME-10-0064. PubMed: 21310893.
15. Kishikawara S, Blumen S, Sekula D, Bissonnette RP, Lamph WW et al. (2008) GOS2 is an all-trans-retinoic acid target gene. Int J Oncol 33: 397-404. PubMed: 18636162.
16. Yang X, Lu X, Lombiès M, Rha GB, Chi Yi et al. (2010) The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with...
adipose triglyceride lipase. Cell Metab 11: 194-205. doi:10.1016/j.cmet. 2010.02.003. PubMed: 20197052.

17. Bächner D, Ahrens M, Schröder D, Hoffmann A, Lauber J et al. (1998) Bmp-2 downstream targets in mesenchymal development identified by subtractive cloning from recombinant mesenchymal progenitors (C3H10T1/2). Dev Dyn. 213: 398-411. doi: 10.1002/sici.1097-0177(199812)213:4. PubMed: 9853961.

18. Herzog S, Hedrick S, Morantte I, Koo SH, Galimi F et al. (2003) CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature 426: 190-193. doi:10.1038/nature02110. PubMed: 14614508.

19. Latruffe N, Passilly P, Jannin B, Motojima K, Cherkauer Malki M et al. (2000) Relationship between signal transduction and PPAR alpha-regulated genes of lipid metabolism in rat hepatic-derived Fao cells. Cell Biochem Biophys 32: 213-220. doi:10.1385/CBB:32:1-3:213. PubMed: 11330049.

20. Edvardsson U, Ljungberg A, Lindén D, William-Olsson L, Peilot-Sjögren H et al. (2006) PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. J Lipid Res 47: 329-340. PubMed: 16282640.

21. Waterman J, Zammit VA (2002) Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 51: 1708-1713. doi: 10.2337/diabetes.51.6.1708. PubMed: 12031956.

22. Ljung B, Bamberg K, Dahllöf B, Kjellstedt A, Oakes ND et al. (2002) AZ and PRV treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 51: 1708-1713. doi: 10.2337/diabetes.51.6.1708. PubMed: 12031956.

23. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C et al. (2002) Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced obesity. J Biol Chem 277: 24484-24489. doi:10.1074/jbc.M204492000. PubMed: 11994294.

24. Huang XS, Zhou GP, Bai L, Hu M, Zhao W et al. (2009) Atorvastatin and fenofibrate increase apolipoprotein A and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Br J Pharmacol 158: 706-712. doi:10.1111/j.1476-5381.2009.03930.x. PubMed: 19694740.

25. Pan SY, Yang R, Dong H, Yu ZL, Ko KM (2006) Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol 552: 170-175. doi:10.1016/j.ejphar.2006.09.011. PubMed: 17049746.

26. Srivastava RA (2009) Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAY mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists. Eur J Pharmacol 607: 258-263. doi:10.1016/j.ejphar.2009.02.024. PubMed: 19245804.

27. Haemmerle G, Moustafa T, Woellert G, Büttner S, Schmidt A et al. (2011) ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 17: 1076-1085. doi: 10.1038/nm.2439. PubMed: 21685160.

28. Ong KT, Mashek MT, Bu SY, Mashek DG (2012) Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation. FASEB J 27: 313-321. PubMed: 22993196.

29. Lu X, Yang X, Liu J (2010) Differential control of ATGL-mediated lipid droplet degradation by CGI-58 and G0S2. Cell Cycle 9: 2719-2725. doi: 10.4161/cc.9.14.12181. PubMed: 20676045.

30. Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332: 1519-1523. doi:10.1126/science.1204265. PubMed: 21700865.

31. Ma L, Robinson LN, Towle HC (2006) ChREBP*Mix is the principal mediator of glucose-induced gene expression in the liver. J Biol Chem 281: 28721-28730. doi:10.1074/jbc.M601576200. PubMed: 16885160.

32. Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H et al. (2003) Hepatic Akt activation induces marked hypoglycemia, hepateomegaly, and hypertriglyceridermia with sterol regulatory element binding protein involvement. Diabetes 52: 2905-2913. doi:10.2337/diabetes.52.12.2905. PubMed: 14633850.

33. Xu A, Lam MC, Chan KW, Wang Y, Zhang J et al. (2005) Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci U S A 102: 6086-6091. doi:10.1073/pnas.0408452100. PubMed: 15837923.

34. Stiles B, Wang Y, Stahl A, Bassillian S, Lee WP et al. (2004) Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc Natl Acad Sci U S A 101: 2082-2087. doi:10.1073/pnas.0308617100. PubMed: 14769918.

35. Hoy AJ, Bruce CR, Turpin SM, Morris AJ, Febbraio MA et al. (2011) Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin resistance despite reduced energy expenditure and ectopic lipid accumulation. Endocrinology 152: 48-58. doi:10.1210/en.2010-0661. PubMed: 21106876.

36. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C et al. (2006) Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312: 734-737. doi:10.1126/science.1123965. PubMed: 16675698.

37. Badin PM, Louche K, Mairal A, Liebisch G, Schmitz G et al. (2011) Altered skeletal muscle lipase expression and activity contribute to insulin resistance in humans. Diabetes 60: 1734-1742. doi:10.2337/db10-1364. PubMed: 21498783.

38. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA et al. (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 108: 16361-16365. doi:10.1073/pnas.1113359108. PubMed: 21930939.